Senile plaque The beta-amyloid peptide (Aβ) is a crucial molecule central to understanding Alzheimer's disease (AD). These peptides, typically ranging from 36 to 43 amino acids in length, are fragments produced from the amyloid precursor protein (APP) through a process involving specific enzymes.作者：Y Zhang·2023·被引用次数：915—Amyloid βprotein (Aβ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as ... While their formation is a normal cellular event, their accumulation and aggregation in the brain are considered a primary driver of Alzheimer's pathology, forming the characteristic senile plaques that disrupt neuronal function.Amyloid β-Targeted Inhibitory Peptides for Alzheimer's Disease Understanding the structure, formation, and pathological role of beta-amyloid peptide is paramount for developing effective diagnostic and therapeutic strategies for AD.
Beta-amyloid peptides are generated from the amyloid precursor protein (APP), a transmembrane protein found in various tissues, particularly in the brain. APP undergoes proteolytic processing, a step-by-step breakdown by enzymes known as secretases. The sequential action of β-secretase (BACE1) and γ-secretase cleaves APP to release Aβ peptides. This processing is a natural biological pathway, meaning Aβ peptides are present in healthy individuals.Amyloid β 1-42 peptide However, in Alzheimer's disease, this process is dysregulated, leading to an overproduction or impaired clearance of Aβ, particularly the longer and more aggregation-prone forms.
Among the various forms of beta-amyloid peptide, two are particularly significant: Aβ(1-40) and Aβ(1-42). These differ in their C-terminal amino acid.作者：X Sun·2015·被引用次数：436—The amyloid β peptide (Aβ) isa critical initiator that triggers the progression of Alzheimer's Disease(AD) via accumulation and aggregation. Aβ(1-42) is considered more hydrophobic and prone to aggregation than Aβ(1-40). This higher propensity for self-assembly means that Aβ(1-42) is believed to be a critical initiator in the cascade of events leading to Alzheimer's disease. Once formed, these peptides can misfold and aggregate, initially forming soluble oligomers, which are thought to be highly toxic to neurons.This peptide functions as aneurotoxic agent in neuronal cell culturesand exhibits pronounced neurotoxicity in various neural cell models. Additionally, it ... These oligomers can then further aggregate into larger, insoluble fibrils that deposit as senile plaques in the extracellular space between brain cellsSynonyms:amyloid β-peptide| beta-amyloid protein ; Compound class: Endogenous peptide in human, mouse or rat ; Comment: ....
The accumulation of beta-amyloid peptide in the brain is a hallmark of Alzheimer's disease. The formation of senile plaques is a key pathological feature, contributing to neuroinflammation and synaptic dysfunction. The presence of these plaques is strongly correlated with cognitive decline and memory loss characteristic of AD.作者：IW Hamley·2012·被引用次数：1076—This review is concerned with the role of fibrillization of theamyloid β(Aβ)-peptidein Alzheimer's disease (AD). The perspective is that of a physical ... While the exact mechanisms by which Aβ induces neurotoxicity are still under investigation, current hypotheses suggest that Aβ oligomers can interfere with synaptic plasticity, disrupt calcium homeostasis, induce oxidative stress, and trigger inflammatory responses, ultimately leading to neuronal degeneration and cell death.
The central role of beta-amyloid peptide in Alzheimer's disease has made it a primary target for therapeutic interventions.Beta-amyloid peptide (beta-APP)is a 40-residue peptideimplicated in the pathogenesis of Alzheimer's disease (AD) and aged Down's Syndrome. Research efforts are focused on several strategies:
* Reducing Aβ Production: Developing drugs that inhibit the activity of β-secretase and γ-secretase to decrease the production of Aβ peptidesAmyloid β-Peptide (1-40) (human).
* Enhancing Aβ Clearance: Investigating methods to promote the removal of Aβ from the brain, such as through immunotherapy or by enhancing the brain's natural waste clearance mechanisms.
* Preventing Aβ Aggregation: Designing molecules that can bind to Aβ peptides and prevent them from forming toxic oligomers or plaques.Alzheimer's: This common virus might be involved in the ...
* Targeting Soluble Oligomers: Developing therapies specifically aimed at neutralizing the neurotoxic effects of soluble Aβ oligomers.
Promising therapeutic developments, such as monoclonal antibodies like Aducanumab and Lecanemab, aim to target and clear amyloid plaques, showing potential in slowing disease progression. These advancements underscore the ongoing effort to combat Alzheimer's disease by directly addressing the role of the beta-amyloid peptideBeta Amyloid(1-42)Peptide(Human) (ab120301) is the predominant amyloid β-peptidefound in plaques associated with Alzheimer's disease (AD)..
The beta-amyloid peptide, a product of APP processing, is inextricably linked to the pathogenesis of Alzheimer's diseaseThe Amyloid Beta Peptide: A Chemist's Perspective. Role in .... Its tendency to aggregate into senile plaques and its neurotoxic oligomeric forms are considered central to the disease's progression作者：G Chen·2017·被引用次数：2717—Amyloid beta peptide (Aβ)is produced through the proteolytic processing of a transmembrane protein, amyloid precursor protein (APP), by β- and γ-secretases.. Continued research into the intricate biology of Aβ, from its formation to its aggregation and toxic mechanisms, remains critical for the development of effective treatments and ultimately, a cure for Alzheimer's disease. Understanding the different variants, their aggregation properties, and their direct impact on neuronal health provides a vital foundation for future therapeutic strategies.
Join the newsletter to receive news, updates, new products and freebies in your inbox.